LOADING
Tag: launch
Leo Pharma prepares to come for the topical JAK market as Incyte’s Opzelura cream launch cools off
May 4, 2024
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several positive studies in hand, including a recent phase 3 trial pitting the candidate against the current standard-of-care, Leo says its delgocitinib has growth driver potential. Now, the drugmaker […]
chat_bubble0 Comment
visibility184 Views